Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / July 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Is Investigating Grifols SA And Encourages Impacted Investors To Initiate Conversations

LOS ANGELES, CA / ACCESSWIRE / July 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA Is Under Examination By The Schall Law Firm, Investors Who Have Been Affected Are Urged To Start Dialogues

LOS ANGELES, CA / ACCESSWIRE / July 16, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Encourages Affected Investors To Initiate Conversation, Grifols SA Is Under Scrutiny

Grifols faces challenges with high debt levels and difficulty in refinancing, leading to a downgrade in corporate rating by Moody's. Q1 results were not encouraging, especially in terms of cash generation. The focus is now on the Q2 results. Is going private the solution? Brookfield Asset Management is in talks with Grifols' majority shareholders to potentially privatize the company.

Grifols: Going Private? Brookfield On The Scene

LOS ANGELES, CA / ACCESSWIRE / July 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA Under Investigation By The Schall Law Firm Urging Impacted Investors To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA Under Scrutiny By The Schall Law Firm Encourages Affected Investors To Commence Conversation

LOS ANGELES, CA / ACCESSWIRE / July 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Initiates Investigation Into Allegations Against Grifols SA Urging Impacted Investors To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Grifols SA Under Scrutiny By The Schall Law Firm Urging Affected Investors To Initiate Conversation

LOS ANGELES, CA / ACCESSWIRE / July 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Probe Into Allegations Against Grifols SA Is Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Investigation Into Claims Against Grifols SA Is Started By The Schall Law Firm And Affected Investors Are Urged To Begin Communication

American depositary receipts (ADRs) of Grifols (GRFS) gained for a second day Tuesday on word Canadian investment manager Brookfield and family member shareholders are in talks to take the Spanish pharmaceutical company private.

Grifols Family Shareholders, Brookfield in Talks To Take Firm Private

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Examination Into Allegations Against Grifols SA Is Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Commence Communication

Grifols (NASDAQ: GRFS ) stock is jumping on Monday after investors learned that the founding family of the company is considering a takeover offer that would see it go private. The Grifols family is working alongside Brookfield on an offer that would result in a takeover of the business.

GRFS Stock Alert: Grifols Pops 20% on Takeover Interest

Shares of Grifols were halted on Monday, following news the Spanish blood plasma pharmaceutical company may go private in a deal with Canadian investment managing group Brookfield Capital Partners.

Troubled Spanish pharma company Grifols says it may go private for $6 billion

The Grifols family and Canadian fund Brookfield are in talks to launch a takeover bid for Spanish drugmaker Grifols that could be worth around 5.5 billion euros ($5.95 billion), business newspaper Cinco Dias reported on Sunday, citing unnamed people familiar with the plans.

Grifols family, Brookfield eye $6 bln takeover bid for Grifols, report says

LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Starts Scrutiny Of Allegations Against Grifols SA And Promotes Investors With Losses To Initiate Communication

LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Investigation Into Grifols SA Is Launched By The Schall Law Firm And It Motivates Affected Investors To Commence Dialogue

LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Initiates Examination Into Accusations Against Grifols SA And Encourages Impacted Investors To Start Interaction

Spanish drugmaker Grifols has appointed Rahul Srinivasan as chief financial officer, the company said on Thursday, as the company reshuffles management after a short-seller fund questioned its accounting.

Spanish drugmaker Grifols appoints new finance chief as shake-up continues

LOS ANGELES, CA / ACCESSWIRE / July 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Commences Inquiry Into Allegations Against Grifols SA And Urges Affected Investors To Initiate Communication

LOS ANGELES, CA / ACCESSWIRE / July 2, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

Probe Into Claims Against Grifols SA Initiated By The Schall Law Firm And Impacted Investors Are Encouraged To Start Contact

Scranton Enterprises, an entity tied to the Grifols family, said on Tuesday it has reached an agreement with a private investor to refinance 377 million euros ($404.5 million) in debt of one of its units.

Unit of Grifols shareholder Scranton reaches debt refinancing deal

BARCELONA, Spain, July 01, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest, a Grifols Group company, forecasts approximately USD 1 billion in revenue from sales in the United States of its intravenous immunoglobulin (Ig) Yimmugo ® during the next seven years, following recent Food and Drug Administration (FDA) approval to treat primary immunodeficiencies (PID).

Grifols' Biotest to achieve USD 1 billion in US sales of Yimmugo® over next seven years

LOS ANGELES, CA / ACCESSWIRE / June 28, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

The Schall Law Firm Begins Probe Into Claims Against Grifols SA And Urges Affected Investors To Initiate Contact

LOS ANGELES, CA / ACCESSWIRE / June 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

News for Grifols, S.A. Stock (GRFS)